Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dutch biopharmaceutical company Crucell has announced that the Chinese authorities have released Hepavax-Gene for registration and quality control in China.
Subscribe to our email newsletter
Hepavax-Gene is a recombinant hepatitis B vaccine. It is said to be one of the World Health Organization’s pre-qualified vaccines for immunization against hepatitis B virus.
According to the company, Hepavax-Gene possesses two decisive advantages; its production is based on Crucell’s hansenula polymorpha patented technology and it is 100% free of thiomersal.
Ronald Brus, CEO of Crucell, said: “The launch of Hepavax-Gene is a significant advancement in the expansion of Crucell’s business in the Chinese vaccine market. Hepavax-Gene will contribute significantly to the sustainability of our Chinese operations.”